Compass Therapeutics, Inc.
CMPX
Positions held
Your positionsCMPX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $177.10M | Enterprise value | $6.85M | Trailing P/E | — | Forward P/E | -1.83 |
| PEG | — | Price / book | 1.07 | Beta | 0.91 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -56.7% | ROA | -33.0% | Debt / equity | 0.06 |
| Current ratio | 11.22 | Free cash flow | -$31.36M | Analyst recommendation | none | Mean target | $5.45 |
| 52w high | $6.88 | 52w low | $0.83 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$25.2M | -$18.3M | -$15.7M | -$14.3M | -$19.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.0M | -$20.3M | -$18.0M | -$15.8M | -$21.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.8M | $0.0M | $0.0M | — |
| Op margin | — | -6661.8% | — | — | — |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Sector Update: Healthcare Stocks Decline Late Afternoon
2026-09-23 · Sector Update: Healthcare
2026-09-23 · Compass Therapeutics Shares Drop After Downgrade From Wedbush
2026-09-23 · Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5
2026-09-22 · CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
2026-09-22 · Sector Update: Healthcare Stocks Rise Late Afternoon
2026-09-22 · Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
2026-09-22 · Sector Update: Healthcare Stocks Rise Tuesday Afternoon
2026-09-22 · CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing
2026-09-22 · Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall
2026-09-22 · Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Price (daily)
Full chart · RSI · MACD · patterns